Head and Neck Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095 Guangdong Province, China.
Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Biomed Res Int. 2018 Dec 18;2018:6942829. doi: 10.1155/2018/6942829. eCollection 2018.
Previous studies have examined the effect of the initiation time of renal replacement therapy (RRT) in patients with cardiac surgery-associated acute kidney injury (CSA-AKI), but the findings remain controversial. The aim of this meta-analysis was to systematically and quantitatively compare the impact of early versus late initiation of RRT on the outcome of patients with CSA-AKI.
Four databases (PubMed, the Cochrane Library, ISI Web of Knowledge, and Embase) were systematically searched from inception to June 2018 for randomized clinical trials (RCTs). Two investigators independently performed the literature search, study selection, data extraction, and quality evaluation. Meta-analysis and trial sequential analysis (TSA) were used to examine the impact of RRT initiation time on all-cause mortality (primary outcome). The Grading of Recommendations Assessment Development and Evaluation (GRADE) was used to evaluate the level of evidence.
We identified 4 RCTs with 355 patients that were eligible for inclusion. Pooled analyses indicated no difference in mortality for patients receiving early and late initiation of RRT (relative risk [RR] = 0.61, 95% confidence interval [CI] = 0.33 to 1.12). However, the results were not confirmed by TSA. Similarly, early RRT did not reduce the length of stay (LOS) in the intensive care unit (ICU) (mean difference [MD] = -1.04; 95% CI = -3.34 to 1.27) or the LOS in the hospital (MD = -1.57; 95% CI = -4.62 to 1.48). Analysis using GRADE indicated the certainty of the body of evidence was very low for a benefit from early initiation of RRT.
Early initiation of RRT had no beneficial impacts on outcomes in patients with CSA-AKI. Future larger and more adequately powered prospective RCTs are needed to verify the benefit of reduced mortality associated with early initiation of RRT.
This trial is registered with PROSPERO registration number CRD42018084465, registered on 11 February 2018.
先前的研究已经探讨了心脏手术后急性肾损伤(CSA-AKI)患者开始肾脏替代治疗(RRT)的时间对患者结局的影响,但研究结果仍存在争议。本荟萃分析的目的是系统地定量比较早期与晚期开始 RRT 对 CSA-AKI 患者结局的影响。
从创建到 2018 年 6 月,我们系统地检索了 4 个数据库(PubMed、Cochrane 图书馆、ISI Web of Knowledge 和 Embase)以查找随机临床试验(RCT)。两位研究者独立进行文献检索、研究选择、数据提取和质量评估。Meta 分析和试验序贯分析(TSA)用于评估 RRT 起始时间对全因死亡率(主要结局)的影响。使用推荐评估、制定与评价(GRADE)分级评估证据水平。
我们共确定了 4 项符合纳入标准的 RCT,共纳入 355 例患者。汇总分析表明,早期与晚期开始 RRT 的患者死亡率无差异(相对风险 [RR] = 0.61,95%置信区间 [CI] = 0.33 至 1.12)。然而,TSA 并未证实这一结果。同样,早期 RRT 并未缩短 ICU 入住时间(MD = -1.04;95% CI = -3.34 至 1.27)或医院住院时间(MD = -1.57;95% CI = -4.62 至 1.48)。使用 GRADE 进行分析表明,早期开始 RRT 可降低死亡率的获益证据质量非常低。
早期开始 RRT 对 CSA-AKI 患者的结局无获益影响。未来需要更大规模且充分有力的前瞻性 RCT 来验证早期开始 RRT 降低死亡率的获益。
本试验在 PROSPERO 注册(注册号 CRD42018084465),于 2018 年 2 月 11 日注册。